FDAnews
www.fdanews.com/articles/75347-taro-receives-approval-to-market-generic-loprox

TARO RECEIVES APPROVAL TO MARKET GENERIC LOPROX

August 12, 2005

The FDA has approved Taro Pharmaceutical Industries' abbreviated new drug application for Ciclopirox Topical Suspension USP, 0.77 percent.

Taro's product is the generic equivalent of Medicis Pharmaceutical's Loprox, which is intended to treat fungal infections of the skin. Ciclopirox topical suspension products had annual U.S. sales of approximately $34.2 million in 2004, Taro said.